Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
613 Leser
Artikel bewerten:
(2)

EQS-News: AID GENOMICS: Hope is coming to Gaza: BGI and AID to set up lab testing 3000 people a day

EQS-News / 06/04/2020 / 23:40 UTC+8 
 
With the approval of both Israeli and Palestinian authorities, AID GENOMICS 
announce to launch an emergency testing Laboratory to perform 3,000 COVID-19 
tests daily for Gaza residents. BGI is the partner to provide technology 
support. 
 
The Lab shall cost a few million dollars, AID GROUP will lead the donation. 
Prospective donors may contact AID Genomics in Israel. Mammoth Foundation 
also announced to join the donation and organize fund-raising in China for 
GAZA Lab operation. 
 
      For the first time in the history, Palestinian and Israeli authorities 
  mutually agree on a common goal. "Peace" is the result of mankind's common 
    enemy - the novel corona virus. BGI from China, which is one of the most 
      prominent suppliers of COVID19 PCR tests in the world, has bridged the 
 borders of the Gaza strip. BGI is collaborating with their Israeli partner, 
 AID Genomics, to build a laboratory in Gaza that will provide 3,000 tests a 
                                                                        day. 
 
 "With the approvals from both sides of the Gaza border, people in Gaza will 
   see hope in defeating COVID19 as well as a light of peace in the future." 
                               This represents the many Gaza people's voice. 
 
"The worst of times reveals the best in people, saving lives is of paramount 
     importance", said Dr. Ye Yin, the CEO of BGI, "we must work together to 
   surmount whatever difficulty that lies ahead." BGI, as a leading genomics 
   company, brings the HuoYan Lab solution from China. Mammoth Foundation, a 
charity in Shenzhen, China, also announced to join the donation and organize 
                               fund-raising in China for GAZA Lab operation. 
 
The AID Group already supplied hundreds of thousands of test kits, developed 
 by BGI, to the State of Israel. BGI is the largest DNA and Genomics company 
      in the world. Today, AID announced an extraordinary initiative for the 
        people of Gaza and the Palestinian Authority with the support of the 
        authorities' special approvals and the technology transfer from BGI. 
 
According to Snir Zano, the CEO of AID GENOMICS: "In the past months, we are 
  working with BGI at full speed to assist as much as we can. To my delight, 
 as an Israeli, our proposal was approved by the Palestinian Authorities and 
other relevant departments. We have then received calls from various parties 
       around the world to show their support. We are fortunate that Mammoth 
 Foundation and my Chairman's, Kelvin Wu, philanthropic family arm, i-Future 
Foundation, are the first to lead the donation. The lab will be a HuoYan Lab 
                Solution and be ready to perform up to 3,000 tests per day." 
 
      According to Kelvin Wu, the Founder and Chairman of AID Group: "We are 
  humbled to receive the support from BGI that derived from our two years of 
  continuous R&D collaboration in cancer genomics. When it comes to illness, 
    it is a common challenge to humanity. We are wholeheartedly committed to 
                                        winning the fight against diseases." 
 
    BGI was one of the first institutes to examine the virus that erupted in 
  Wuhan. In light of the lack of test throughput, BGI built the first HuoYan 
   Laboratory in Wuhan in Feb; after that, four more in other bigger cities. 
 
    Altogether, the HuoYan Labs have performed 500,000+ Coronavirus tests in 
    China. This vast testing capability has enabled a fast reaction time and 
  rapid treatment for those found infected to the virus, even in incubation. 
   Today, dozens of countries want the aid of the HuoYan Labs. AID is in the 
                            process of bringing the labs to Gaza and Israel. 
 
Document: https://eqs-cockpit.com/c/fncls.ssp?u=FCCBNIDCAO [1] 
Document title: Hope is coming to Gaza: BGI and AID to set up lab testing 
3000 people a day 
 
06/04/2020 Dissemination of a Marketing Press Release, transmitted by EQS 
Group. 
The issuer is solely responsible for the content of this announcement. 
 
Media archive at www.todayir.com 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cf7ced5d3efceef54dad134bfa6f4bec&application_id=1016511&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

April 06, 2020 11:40 ET (15:40 GMT)

© 2020 Dow Jones News
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.